N/A N=300 Transplant Social Worker Support for Live Kidney Donation in African Americans
Kidney Disease
Primary: Number of Participants With Live Kidney Donor Activation Events — 87; 86; 88; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=378 Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Participants With ACC Count = 0 at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication — 48; 10 Participants — p=<0.001
Phase 2 N=171 A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
NonSegmental Vitiligo
Primary: Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24 — 2.29; -19.12; -17.78; -15.73 percent change — p=0.0015
Phase 2 N=89 A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Pharmacokinetics Measurement — 362028.656; 352248.907 mU*day/mL — p=0.05
N/A N=178 CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.
Covid19 · Mental Health Issue · Violence
Primary: Mean Number of Five Protective COVID-19 Risk Measures — 2.79; 2.66 score on a scale — p=0.28
Phase 2 N=281 A Study of LY3437943 in Participants With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.05; -1.41; -0.43; -1.39 percentage of HbA1c — p=0.188
Phase 4 N=270 Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
Hepatitis B, Chronic
Primary: Number of Participants With HBV DNA <20 IU Per mL — 257; 261; 257; 256 Participants
Phase 3 N=193 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Recurrent Adult Primary Liver Cancer
Primary: Overall Survival — 12.30; 15.85 months — p=0.0554
Phase 2 N=49 Neuromuscular Blockade in Patients With Severe Renal Impairment
Neuromuscular Blockade · Renal Impairment
Primary: Time Until Complete Reversal of Neuromuscular Blockade — 14.8; 3.5 Minutes
Phase 2 N=50 Blood Pressure Lowering in Dialysis (BOLD) Trial
Blood Pressure · End Stage Renal Disease on Dialysis (Diagnosis) · Chronic Kidney Diseases
Primary: Feasibility - Screen:Enrollment Ratio — 50 Participants
Phase 2 N=307 Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
End Stage Renal Disease Requiring Hemodialysis
Primary: Incidence of Composite of Major Bleeding (MB) and Clinically-relevant Non-major Bleeding (CRNMB) During the Main Treatment Period and Within the On-treatment Time…
Phase 2 N=91 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
Pancreatic Adenocarcinoma
Primary: Rate of Progression-free Survival at 6 Months (PFS6) — 20.6; 59.6 percentage of participants with PFS
Phase 2 N=21 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
Phase 3 N=517 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Alopecia Areata
Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24 — 0.8; 33.0; 38.3 Percentage of participants — p=<0.0001
N/A N=30 Clinical Evaluation of the Safety and Efficacy of a 1060nm Diode Laser (Abdomen)
Fat Atrophy
Primary: Number of Before and After Photograph Sets Correctly Identified by Independent, Blinded Evaluators — 54 Photo sets